

Injectable Vaccine Administration for Adults Aged 19 Years and Older¹

Vaccine	Age/Reminders	Route	Contraindications ²
Tetanus, diphtheria (Td)	Ages 7 years & older; boost every 10 years after completion of pertussis-containing series	IM	Anaphylactic reaction to prior dose or component
Tetanus, diphtheria, pertussis (Tdap) ³	Give a single dose for all ages, including those aged 65 years & older; 1 dose during each pregnancy, preferred during early part of gestational weeks 27 through 36 weeks	IM	Anaphylactic reaction to prior dose or component; encephalopathy without other cause within 7 days of a pertussis-containing vaccine
Hepatitis B (HepB)	Use pediatric formulation for persons aged 19 years & younger when indicated; use adult formulation for persons aged 20 years & older when indicated	IM*	Anaphylactic reaction to prior dose or component; hypersensitivity to yeast
Hepatitis A (HepA)	Give 2 doses when indicated; doses must be at least 6 months apart; use adult formulation for 19 years & older	IM	Anaphylactic reaction to prior dose or component
Measles, Mumps, Rubella (MMR)	Give 1 dose if born in 1957 or later; give 2 doses at least 4 weeks apart to adults at high risk	SC	Anaphylactic reaction to prior dose or component; pregnancy; immune suppression ²
Varicella (Var)	Give 2 doses at least 4 weeks apart to adults without evidence of immunity (e.g. born in U.S. before 1980, healthcare provider verification of disease)	SC	Anaphylactic reaction to prior dose or component; pregnancy; immune suppression ²
Inactivated Influenza ⁴	Give 1 dose every flu season (July 1 st through June 30 th)	IM* or ID	Anaphylactic reaction to prior dose or component
Pneumococcal Conjugate (PCV13) ⁵	Ages 65 years & older if previously unvaccinated give 1 dose; ages 19-64 years if previously unvaccinated may need 1 dose based on risk condition ⁵	IM	Anaphylactic reaction to prior dose or component or any diphtheria toxoid-containing vaccine
Pneumococcal Polysaccharide (PPSV23) ⁵	Ages 65 years & older give 1 dose; ages 2-64 years may need 1-2 doses based on risk condition; minimum interval between doses is 5 years for all ages	IM or SC	Anaphylactic reaction to prior dose or component
Meningococcal Conjugate (MenACWY) ⁶	Ages 2 months-55 years when indicated; may be given to ages 56 years & older; not routinely recommended for persons aged 21 years & older without a risk condition	IM	Anaphylactic reaction to prior dose or component
Meningococcal B (MenB)	Ages 10 years & older when indicated; may vaccinate ages 16-23 years (Category B recommendation ⁷)	IM	Anaphylactic reaction to prior dose or component
Human Papillomavirus (9vHPV)	2- or 3-dose series depending on person's health status and age when the HPV vaccine series was started; catch up females through age 26 years; catch up males through age 21 years and high-risk males 22-26 years (immunocompromised, men who have sex with men, transgender)	IM*	Anaphylactic reaction to prior dose or component; not recommended for use in pregnancy

See footnotes on page 2.

Injectable Vaccine Administration for Adults Aged 19 Years and Older¹

Vaccine	Age/Reminders	Route	Contraindications ²
Recombinant Zoster Vaccine (RZV, Shingrix)	Preferred zoster vaccine for adults aged 50 years and older; give 2 doses 2-6 months apart	IM	Anaphylactic reaction to prior dose or component
Zoster Vaccine Live (ZVL, Zostavax [®])	Adults age 60 years & older, give 1 dose	SC	Anaphylactic reaction to prior dose or component; pregnancy; immune suppression ²

Route	Site	Needle length/gauge
IM = Intramuscular	Deltoid (preferred) or anterolateral thigh	1-1.5 inches, 22-25 gauge
SC = Subcutaneous	Lateral upper arm or anterolateral thigh area	5/8 inch, 23-25 gauge
ID = Intradermal	Area over deltoid	For ID flu vaccine, only use manufacturer's prefilled syringe

*Certain vaccines given by the wrong route should not be counted as valid and should be repeated: hepatitis B, inactivated influenza, and HPV. There is no minimum interval between the invalid (e.g. subcutaneous) dose and the repeat dose.

¹For information on travel vaccines, refer to [CDC Travel Vaccines](http://wwwnc.cdc.gov/travel) (URL: wwwnc.cdc.gov/travel). For more information on vaccines for adults, including *Haemophilus influenzae* type b (Hib), refer to the “Recommended Adult Immunization Schedule” including footnotes at [CDC Vaccines & Immunizations](http://www.cdc.gov/vaccines) (URL: www.cdc.gov/vaccines). For vaccine-specific recommendations refer to the [Advisory Committee for Immunization Practices \(ACIP\) Vaccine Recommendations and Guidelines](http://www.cdc.gov/vaccines/hcp/acip-recs/index.html) (URL: www.cdc.gov/vaccines/hcp/acip-recs/index.html).

²See package inserts for complete component listing (by brand). Refer to [ACIP General Best Practice Guidelines for Immunization](http://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html) (URL: www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html), and the [Pink Book](http://www.cdc.gov/vaccines/pubs/pinkbook/index.html) (URL: www.cdc.gov/vaccines/pubs/pinkbook/index.html) for a comprehensive list of vaccine contraindications and precautions. For MMR, varicella, and ZVL check which immune suppressing conditions are considered as contraindications to vaccination.

³Tdap licensure ages: Boostrix[®] (GSK) ages 10 years and older; Adacel[®] (Sanofi) for ages 10-64 years. Either brand may be used for children aged 7-10 years; for persons 65 years & older, Boostrix[®] is preferred, but if unavailable Adacel[®] may be used.

⁴Age indications for influenza vaccines vary by brand. For more information on flu vaccines, refer to the package inserts, [CDC Influenza](http://www.cdc.gov/flu) (URL: www.cdc.gov/flu), or [MDHHS Influenza](http://www.michigan.gov/flu) (URL: www.michigan.gov/flu) (Current Flu Season Vaccination Materials for Health Care Professionals).

⁵PCV13 should be administered prior to PPSV23; use a minimum interval of 8 weeks between PCV13 (if given 1st) and PPSV23. If PPSV23 is given 1st, use minimum interval of 1 year before administering PCV13. Refer to the “Recommended Adult Immunization Schedule” including footnotes at [CDC Vaccines & Immunizations](http://www.cdc.gov/vaccines) (URL: www.cdc.gov/vaccines). For further guidance regarding pneumococcal vaccines and intervals between pneumococcal vaccine doses refer to “[Pneumococcal Vaccine Timing for Adults](http://www.michigan.gov/documents/mdhhs/Pneumo_Timing_Mich_611960_7.pdf)” (URL: http://www.michigan.gov/documents/mdhhs/Pneumo_Timing_Mich_611960_7.pdf).

⁶MenACWY licensure ages: Menveo[®] (GSK) ages 2 months-55 years; Menactra[®] (Sanofi Pasteur) ages 9 months-55 years.

⁷Refer to, “[Understanding the Category B Recommendation for Serogroup B Meningococcal Vaccine](http://pediatrics.aappublications.org/content/early/2017/03/31/peds.2016-3484),” published in *Pediatrics* in April 2017 (URL: <http://pediatrics.aappublications.org/content/early/2017/03/31/peds.2016-3484>).